Duloxetine Capsule, Delayed Release
Product Images NDC 68788-7672

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-7672). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed Release Cap Usp 60mg

Label for Duloxetine Delayed-Release Capsules USP 60 mg by Preferred Pharmaceuticals, Inc. The label states the capsules contain 67.3 mg of duloxetine hydrochloride equivalent to 60 mg of duloxetine. It is a delayed-release oral capsule, generic for Cymbalta, manufactured by Ajanta Pharma USA Inc. The label includes storage instructions and a barcode, with dosing directions printed in both English and Spanish.*

FDA Label Image

Duloxetine Fig1

Kaplan-Meier curve showing the proportion of patients with relapse over time in days from randomization for Duloxetine and placebo treatment groups. The graph compares relapse rates between Duloxetine (solid line) and placebo (dashed line), with time on the x-axis and proportion of patients with relapse on the y-axis.*

FDA Label Image

Duloxetine Fig10

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline (BOCF). It compares two groups: placebo and Duloxetine 60/120 mg once daily. The Duloxetine group shows a higher percentage of patients improved across increasing levels of pain improvement compared to placebo.*

FDA Label Image

Duloxetine Fig2

A Kaplan-Meier curve showing the proportion of patients with relapse over time from randomization to relapse (days). The graph compares two treatments: placebo (dashed line) and duloxetine (solid line), with duloxetine showing a lower proportion of relapse over the study period.*

FDA Label Image

Duloxetine Fig3

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo treatments. The graph plots patient improvement percentages against incremental thresholds of pain improvement, illustrating differences among the four groups.*

FDA Label Image

Duloxetine Fig4

A line graph showing the percentage of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. It compares results for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups, illustrating varying degrees of pain improvement with duloxetine treatments compared to placebo.*

FDA Label Image

Duloxetine Fig5

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, illustrating trends in patient improvement over different pain reduction percentages.*

FDA Label Image

Duloxetine Fig6

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine at doses of 120 mg, 60 mg, and 20 mg once daily with a placebo group. The graph shows decreasing percentages of patients as pain improvement percentage increases from greater than 0 to 100.*

FDA Label Image

Duloxetine Fig8

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines represent placebo and Duloxetine 60/120 mg once daily. The graph illustrates comparative effects on patient pain improvement over a range of percent improvement intervals from greater than 0 to 100.*

FDA Label Image

Duloxetine Fig9

A line chart comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for Placebo and Duloxetine 60 mg once daily. The graph shows patient improvement decreasing as percent pain improvement increases, with Duloxetine consistently showing higher improvement percentages than Placebo across the range.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride. The diagram depicts the molecular arrangement including aromatic rings, a sulfur-containing thiophene ring, and functional groups consistent with the duloxetine molecule in its hydrochloride form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.